Total at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s total.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s total?
- Spyre Therapeutics, Inc. (SYRE) reported total of $645.05M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s total changed year-over-year?
- Spyre Therapeutics, Inc.'s total increased by 25.1% year-over-year, from $515.68M to $645.05M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s total has grown at a 217.8% compound annual growth rate (CAGR), from $20.88M to $669.94M.